Download PDF
Fortschr Neurol Psychiatr 2004; 72(12): 705-726
DOI: 10.1055/s-2004-818454
Fort- und Weiterbildung
© Georg Thieme Verlag Stuttgart · New York

Akuttherapie der Schizophrenie

Acute Treatment of SchizophreniaT.  Wobrock1 , P.  Falkai1 , F.-G.  Pajonk1
  • 1Universitäts-Nervenklinik - Psychiatrie und Psychotherapie - Universitätskliniken des Saarlandes, Homburg/Saar (Direktor: Prof. Dr. med. P. Falkai)
Further Information

Publication History

Publication Date:
06 December 2004 (online)

Also available at
    Permissions and Reprints

Lernziel

Für die Therapie schizophrener Störungen stehen mehrere, mittlerweile zum überwiegenden Teil auch evidenzbasierte, Behandlungsverfahren zur Verfügung. Hierbei sollten die individuellen Bedürfnisse des an einer Schizophrenie erkrankten Patienten und die aus der Symptomatik im Einzelfall resultierenden Erforderlichkeiten in ein phasenspezifisches, mehrdimensionales Behandlungskonzept eingebettet werden. Der vorliegende Beitrag stellt die wichtigsten Elemente in der Akuttherapie unter Berücksichtigung allgemeiner, pharmakotherapeutischer und psychotherapeutischer Aspekte dar. Darüber hinaus soll eine Orientierungshilfe für spezielle Behandlungssituationen gegeben werden.

Literatur

  • 1 Addonizio G, Susman V, Roth S. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients.  Am J Psychiatry. 1986;  143 1587-1590
    PubMedGoogle Scholar
  • 2 Allison D B, Mentore J L, Heo M. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
    PubMedGoogle Scholar
  • 3 American Psychiatric Association . Practice guideline for the treatment of patients with schizophrenia. Second edition.  Am J Psychiatry. 2004;  Supplement 1-114
    PubMedGoogle Scholar
  • 4 Azorin J M, Spiegel R, Remington G, Vanelle J M, Péré J J, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.  Am J Psychiatry. 2001;  158 1305-1313
    CrossrefPubMedGoogle Scholar
  • 5 Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.  Prog Neuropsychopharmacol Biol Psychiatry. 2002;  26 1199-1202
    CrossrefPubMedGoogle Scholar
  • 6 Barnas C, Quiner S, Tauscher J, Hilger E, Willeit M, Kufferle B, Asenbaum S, Brucke T, Rao M L, Kasper S. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients.  Psychopharmacology (Berl). 2001;  157 236-242
    CrossrefPubMedGoogle Scholar
  • 7 Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L. et al . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.  Am J Emerg Med. 1997;  15 335-340
    Google Scholar
  • 8 Bench C J, Lammertsma A A, Grasby P M, Dolan R J, Warrington S J, Boyce M, Gunn K P, Brannick L Y, Frackowiak R S. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.  Psychopharmacology. 1996;  124 141-147
    CrossrefPubMedGoogle Scholar
  • 9 Benkert O, Hippius H . Kompendium der Psychiatrischen Pharmakotherapie, 4. Auflage. Berlin, Heidelberg, New York: Springer-Verlag 2003
    Google Scholar
  • 10 Bieniek S A, Ownby R L, Penalver A, Dominguez R A. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation.  Pharmacotherapy. 1998;  18 57-62
    PubMedGoogle Scholar
  • 11 Casey D E, Daniel D G, Wassef A A, Tracy L A, Wozniak P, Sommerville K W. Replyeffect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.  Neuropsychopharmacology. 2003;  28 2052-2053
    PubMedGoogle Scholar
  • 12 Copolov D L, Link C G, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia.  Psychol Med. 2000;  30 95-105
    CrossrefPubMedGoogle Scholar
  • 13 Currier G W, Simpson G M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.  J Clin Psychiatry. 2001;  62 153-157
    PubMedGoogle Scholar
  • 14 Daniel D G, Potkin S G, Reeves K R, Swift R H, Harrigan E P. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.  Psychopharmacology (Berl). 2001;  155 128-134
    CrossrefPubMedGoogle Scholar
  • 15 Davis J M, Chen N, Glick I D. A meta-analysis of the efficacy of second-generation antipsychotics.  Arch Gen Psychiatry. 2003;  60 553-564
    CrossrefPubMedGoogle Scholar
  • 16 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (Hrsg) .Praxisleitlinien in Psychiatrie und Psychotherapie (Band 1). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff 1998
    Google Scholar
  • 17 Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures.  Neurology. 1991;  41 369-371
    CrossrefPubMedGoogle Scholar
  • 18 Drury V, Birchwood M, Cochrane R. Cognitive therapy and recovery from acute psychosis: a controlled trial.  Br J Psychiatry. 2000;  177 8-14
    CrossrefPubMedGoogle Scholar
  • 19 Falloon I RH. Family interventions for mental disorders: efficacy and effectiveness.  World Psychiatry. 2003;  2 20-28
    PubMedGoogle Scholar
  • 20 Fenton M K, Coutinho E SF, Campbell C. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.  (Cochrane-Review). In: The Cochrane Library, Issue 2, 2003. Oxford, Update Software
    Google Scholar
  • 21 Foster S, Kessel J, Berman M E, Simpson G M. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting.  Int Clin Psychopharmacol. 1997;  12 175-179
    PubMedGoogle Scholar
  • 22 Freudenreich O, Goff D C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.  Acta Psychiatr Scand. 2002;  106 323-330
    CrossrefPubMedGoogle Scholar
  • 23 Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.  Schizophr Res. 2002;  53 145-159
    Google Scholar
  • 24 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  BMJ. 2000;  321 1371-1376
    CrossrefPubMedGoogle Scholar
  • 25 Gefvert O, Bergstrom M, Laangstrom B, Lundberg T, Lindstrom I, Yates R A. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuitation of quetiapine in patients with schizophrenia.  Psychopharmacology. 1998;  135 119-126
    CrossrefPubMedGoogle Scholar
  • 26 Glick I D, Lemmens P, Vester-Blokland E. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.  Int Clin Psychopharmacol. 2001;  16 265-274
    CrossrefPubMedGoogle Scholar
  • 27 Gunasekara N S, Spencer C M, Keating G M. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.  Drugs. 2002;  62 1217-1251
    CrossrefPubMedGoogle Scholar
  • 28 Henderson D, Nasrallah R, Goff D. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.  J Clin Psychiatry. 1998;  59 585-588
    PubMedGoogle Scholar
  • 29 Hogarty G E, Anderson C M, Reiss D J, Kornblinth S J, Greenwald P, Javan C D, Manonia M J,. EPICS research group . Family psychoeducation, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia.  Arch Gen Psychiatry. 1986;  43 633-642
    CrossrefPubMedGoogle Scholar
  • 30 Hori M, Suzuki T, Sasaki M, Shiraishi H, Koizumi J. Convulsive seizures in schizophrenic patients induced by zotepine administration.  Jpn J Psychiatry Neurol. 1992;  46 161-167
    PubMedGoogle Scholar
  • 31 Johns C, Thompson J. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy.  Schizophr Bull. 1995;  21 607-619
    CrossrefPubMedGoogle Scholar
  • 32 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.  Arch Gen Psychiatry. 1988;  45 789-796
    Google Scholar
  • 33 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors.  J Clin Psychopharmacol. 1988;  8 52-56
    PubMedGoogle Scholar
  • 34 Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.  Am J Psychiatry. 1996;  153 948-950
    PubMedGoogle Scholar
  • 35 Kapur S, Zipursky R B, Remington G. Clinical and theoretical implication of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.  Am J Psychiatry. 1999;  156 286-293
    PubMedGoogle Scholar
  • 36 Kapur S, Zipursky R B, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.  Am J Psychiatry. 2000;  157 514-520
    CrossrefPubMedGoogle Scholar
  • 37 Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up.  Br J Psychiatry. 1998;  172 413-419
    CrossrefPubMedGoogle Scholar
  • 38 Kopala L C, Good K P, Honer W G. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low dose risperidone.  J Clin Psychopharmacol. 1997;  17 308-313
    CrossrefPubMedGoogle Scholar
  • 39 Koro C E, Fedder D O, L'Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.  Arch Gen Psychiatry. 2002;  59 1021-1026
    PubMedGoogle Scholar
  • 40 Krausz M, Moritz S, Lambert M, Naber D. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.  Int J Psychopharmacol. 2000;  2 77-81
    PubMedGoogle Scholar
  • 41 Lehmann A F, Steinwachs D M,. PORT Co-investigators . Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.  Schizophr Bull. 1998;  24 1-10
    PubMedGoogle Scholar
  • 42 Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.  Clin Neuropharmacol. 2000;  23 284-286
    CrossrefPubMedGoogle Scholar
  • 43 Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, Siddle R, Drake R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Faragher B, Dunn G. Randomised controlled trial of cognitive-behavioral therapy in early schizophrenia: acute-phase outcomes.  Br J Psychiatry (Suppl.). 2002;  43 S91-S97
    PubMedGoogle Scholar
  • 44 Lieberman J A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.  J Clin Psychiatry. 1996;  57 (Suppl. 11) 68-71
    PubMedGoogle Scholar
  • 45 Lieberman J A, Koreen A, Chakos M, Sheitman B, Woerner M, Alvir J M, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.  J Clin Psychiatry. 1996;  57 (Suppl. 9) 5-9
    PubMedGoogle Scholar
  • 46 Lieberman J A, Tollefson G, Tohen M, Green A I, Gur R E, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer R M. HGDH Study Group . Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.  Am J Psychiatry . 2003;  160 1396-1404
    CrossrefPubMedGoogle Scholar
  • 47 Lindenmayer J P, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, Czobor P, Parker B, Iskander A. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.  J Clin Psychopharmacol.. 2001;  21 448-453
    CrossrefPubMedGoogle Scholar
  • 48 Loebel A D, Lieberman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R. Duration of psychosis and outcome in first episode schizophrenia.  Am J Psychiatry. 1992;  149 1183-1188
    PubMedGoogle Scholar
  • 49 Martinot J L, Paillere-Martinot M L, Poirier M F, Dao-Castellana M H, Loch C, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.  Psychopharmacology (Berl). 1996;  124 154-158
    CrossrefPubMedGoogle Scholar
  • 50 McGorry P D, Edwards J, Mihalopoulos C. EPPIC: an evolving system of early detection and optimal management.  Schizophr Bull. 1996;  22 305-322
    Google Scholar
  • 51 Möller H J, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbation of schizophrenia with amisulpride: a comparison with haloperidol.  Psychopharmacology. 1997;  132 396-401
    CrossrefPubMedGoogle Scholar
  • 52 Mullen J, Jibson M D, Sweitzer D. for the QUEST Study Group . A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.  Clin Ther. 2001;  23 1839-1854
    CrossrefPubMedGoogle Scholar
  • 53 National Institute for Clinical Excellence .Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE Technology Appraisal Guidance - No. 43. 2002
    Google Scholar
  • 54 Nordstrom A L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedval G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.  Am J Psychiatry. 1995;  152 1444-1449
    PubMedGoogle Scholar
  • 55 Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.  Am J Psychiatry. 1999;  156 869-875
    PubMedGoogle Scholar
  • 56 Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole.  Psychopharmacology (Berl). 2002;  162 37-41
    CrossrefPubMedGoogle Scholar
  • 57 Pajonk F G, Raedler T J, Schreiner A, Wiedemann K. Effectiveness of risperidone in higly agitated schizophrenic patients.  European Neuropsychopharmacol. 2002;  12 (Suppl 3) S276
    PubMedGoogle Scholar
  • 58 Robinson D G, Woerner M G, Alvir J M, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman J A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.  Am J Psychiatry. 1999;  156 544-549
    PubMedGoogle Scholar
  • 59 Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia.  (Cochrane-Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
    Google Scholar
  • 60 Sanger T M, Lieberman J A, Tohen M, Grundy S, Beasley C, Tollefson G D. Olanzapine versus haloperidol treatment in first-episode psychosis.  Am J Psychiatry. 1999;  156 79-87
    PubMedGoogle Scholar
  • 61 Scholer N R. Maintenance medication for schizophrenia: strategies for dose reduction.  Schizophr Bull. 1991;  17 311-324
    PubMedGoogle Scholar
  • 62 Tandon R, Jibson M D. Efficacy of newer generation antipsychotics in the treatment of schizophrenia.  Psychoneuroendocrinology. 2003;  28 9-26
    CrossrefPubMedGoogle Scholar
  • 63 Thayran P, Adams C E. Electroconvulsive therapy for schizophrenia.  (Cochrane-Review). In: The Cochrane Library, Issue 4, 2002. Chichester, UK: John Wiley & Sons, Ltd.
    Google Scholar
  • 64 Tollefson G D, Birkett M A, Kiesler G M, Wood A J,. Lilly Resistant Schizophrenia Study Group . Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.  Biol Psychiatry. 2001;  49 52-63
    CrossrefPubMedGoogle Scholar
  • 65 Bruggen J van, Tijssen J, Dingemans P, Gersons B, Linszen D. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia.  Int Clin Psychopharmacol. 2003;  18 341-346
    PubMedGoogle Scholar
  • 66 Putten T van, Marder S R, Mintz J. A controlled dose comparison of haloperidol of newly admitted schizophrenic patients.  Arch Gen Psychiatry. 1990;  47 754-758
    PubMedGoogle Scholar
  • 67 Volz H P, Pajonk F G. Akuttherapie schizophrener Psychosen. Stuttgart: Thieme-Verlag 2003: S.33-36
    Google Scholar
  • 68 Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomised pilot study.  Prog Neuropsychopharmacol Biol Psychiatry. 2000;  24 911-922
    CrossrefPubMedGoogle Scholar
  • 69 Wetzel H, Bardeleben U von, Holsboer F, Benkert O. Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppelblind-kontrollierte Wirksamkeitsprüfung.  Fortschr Neurol Psychiat. 1991;  59 (Suppl. 1) 23-29
    PubMedGoogle Scholar
  • 70 Wiedemann G, Klingberg S. Psychotherapie produktiver Symptomatik bei Patienten mit schizophrener Psychose.  Nervenarzt. 2003;  74 76-84
    Google Scholar
  • 71 Wright P, Birkett M, David S R, Meehan K, Ferchland I, Alaka K J. et al . Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.  Am J Psychiatry. 2001;  158 1149-1151
    CrossrefPubMedGoogle Scholar

Dr. med. Thomas Wobrock

Universitäts-Nervenklinik - Psychiatrie und Psychotherapie Universitätskliniken des Saarlandes

66421 Homburg/Saar

Email: thomas.wobrock@uniklinik-saarland.de